How to diagnose a lipodystrophy syndrome.

Area of Science:

• Endocrinology and Metabolic Diseases
• Genetics and Rare Diseases
• Dermatology

Background:

• Adipose tissue disorders range from obesity to lipodystrophy, often linked to insulin resistance syndrome, type 2 diabetes, dyslipidemia, and cardiovascular complications.
• Lipodystrophy, a rare condition of adipose tissue absence, is classified as familial or acquired, and generalized or partial.
• Genetic forms include Dunnigan syndrome (laminopathy), rare mutations (PPAR-gamma, Akt2, CIDEC, perilipin, ZMPSTE 24), and generalized forms linked to seipin, FBN1, or BANF1 mutations.

Purpose of the Study:

• To review the spectrum of adipose tissue diseases, focusing on lipodystrophy.
• To classify the various genetic and acquired forms of lipodystrophy.
• To discuss current and potential therapeutic strategies for lipodystrophy and associated metabolic complications.

Main Methods:

• Literature review of adipose tissue diseases, particularly lipodystrophy.
• Classification of lipodystrophy based on genetic and acquired causes, and clinical presentation.
• Analysis of current treatment options, including recombinant leptin and tesamorelin.

Main Results:

• Genetically determined partial lipodystrophy (e.g., Dunnigan syndrome) can involve laminopathy and other systemic issues.
• Rare genetic forms are linked to mutations in genes like PPAR-gamma, Akt2, CIDEC, perilipin, seipin, FBN1, and BANF1.
• Acquired lipodystrophy can be iatrogenic (e.g., HIV treatments, glucocorticosteroids) or autoimmune, sometimes involving complement system anomalies.
• Lipomatosis includes painful adiposis dolorosa and benign multiple lipomatosis (Madelung's disease).
• Some genetic forms are linked to autoinflammatory syndromes (PSMB8) and glycosylation disorders.

Conclusions:

• Understanding the diverse etiologies of lipodystrophy is crucial for accurate diagnosis and management.
• Recombinant leptin shows promise for genetically determined lipodystrophy.
• Therapeutic advances for metabolic syndrome in HIV patients include antiretroviral modifications and tesamorelin.
• Future treatments will depend on further pathophysiological insights into lipodystrophy, particularly laminopathy and lipid droplet disorders.